Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine and TIVA on Endothelial Damage in Rhinoplasty
NCT06897696Phase 4Completed
- Sponsor
- Firat University
- Start
- Apr 2025
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of dexmedetomidine (2 arms), sponsored by Firat University. Primary endpoint: Endothelial damage in patients under general anaesthesia. Started Apr 2025; status: completed.
02
Drugs
dexmedetomidine
Beyond the preview
Go deeper on NCT06897696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06897696.